Sanofi and Regeneron Pharmaceuticals on 24 July pulled off the first US approval of a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor – gaining the FDA's nod for Praluent (alirocumab).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?